To compare efficacy and safety of glucagon-like peptide-1 receptor agonists in people with type 2 diabetes.
| INTRODUCTION
Type 2 diabetes (T2DM) is a chronic metabolic disorder characterized by a complex pathophysiology of progressive β-cell dysfunction and a varying degree of insulin resistance. As the condition progresses, achieving and maintaining glycaemic control becomes a challenge, despite the availability and use of a number of classes of glucoselowering therapies. 1 Current guidelines recommend a patient-centred approach when choosing appropriate glucose-lowering treatments, with the primary goal of achieving individualized glycaemic targets whilst minimizing adverse effects, particularly weight gain and hypoglycaemia. 2 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of therapeutic agent, which provide significant improvement in glycated haemoglobin (HbA1c) values, with the added benefits of promoting weight loss and low risk of hypoglycaemia. [3] [4] [5] [6] Glucagon-like peptide-1 (GLP-1) is a gut hormone produced by the small intestine in response to oral ingestion of glucose, which promotes a glucoregulatory effect by increasing insulin and suppressing glucagon secretion. 7 It also facilitates weight loss by delaying gastric emptying and acting centrally on the satiety centre to reduce food intake. 7 Manipulating the molecular structure of GLP-1 alters its pharmacological properties and produces biological effects that can be exploited clinically. GLP-1RAs are increasingly classified by duration of action into long-acting (albiglutide, dulaglutide, once-weekly exenatide, liraglutide, semaglutide and taspoglutide) and short-acting (twice-daily exenatide and lixisenatide) agents. The American Diabetes Association (ADA)/European Association for the study of Diabetes (EASD) guidelines recommend the use of GLP-1RAs as an adjunctive therapy to lifestyle modification and metformin. 9 However, there are no specific recommendations about which GLP-1RA to choose in clinical practice, possibly because of the limited availability of head-to-head studies comparing the efficacy and safety of GLP-1RAs. 10 When direct comparisons are limited, a mixed-treatment comparison analysis (also known as a network meta-analysis) is regarded as the methodology of choice to compare several treatments. 11, 12 Using this approach and available data, the aim of the present study was to compare the clinical profiles of different GLP-1RAs.
| METHODS

| Data sources and searches
The present study was performed according to a prespecified protocol and the PRISMA guidelines for the conducting and reporting of systematic reviews and meta-analyses (File S1). 11, 13, 14 We searched PubMed, ISI Web of Science and the Cochrane Library for randomized clinical trials (RCTs) published from inception to June 3, 2016 that compared a GLP-1RA with placebo or another GLP-1RA (twicedaily exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, onceweekly exenatide, semaglutide and taspoglutide) in adults with T2DM. 15 Only RCTs published in full were included (abstracts were excluded). We sought additional studies by manually scanning the reference lists of eligible studies and previous systematic reviews and meta-analyses. Although the clinical trials and the development of taspoglutide were discontinued in 2010, we included taspoglutide RCT data as they contribute to indirect estimations. No language restrictions were applied. Details of the search strategy are provided in Figure S1 . 
| Study selection
| Data extraction and quality assessment
Three authors (Z. Z. H., D. P., F. Z.) independently performed the literature search and extracted study data using predefined forms. and on total number of participants and participants with events for dichotomous data (safety outcomes: nausea, vomiting, diarrhoea, all
[total] hypoglycaemic events and injection site reactions). Data were extracted according to the intention-to-treat principle. When it was not possible to obtain efficacy and safety information from the published report, we retrieved data from ClinicalTrials.gov. In case of disagreement between the three reviewers on the eligibility of an article or on extracted data, consensus was reached by re-evaluation of the article and consultation with an independent reviewer. Study quality was assessed using the Cochrane risk-of-bias tool. 16 
| Data synthesis and analysis
We performed a mixed-treatment comparison within a frequentist framework based on the method of multivariate meta-analysis. [17] [18] [19] We used treatment-specific mean difference from baseline and odds ratios (ORs) as effect measures for continuous and dichotomous data, respectively; we added 0.5 when studies reported zero events for safety outcomes. For each outcome, we graphically summarized the evidence using a network diagram 20 and performed random-effects network meta-analyses, assuming that all treatment contrasts had the same heterogeneity variance. We presented results against placebo and comparisons across all GLP-1RAs in graphs and tables. For each outcome, we assessed consistency between direct and indirect evidence using the "design-by-treatment" interaction model. 21 3 | RESULTS
| Study characteristics
We identified 7697 records, of which 34 fulfilled the inclusion criteria ( Figure S1 ). Table S1 ).
| Mixed-treatment comparison
Estimates for cardiometabolic outcomes are shown in Figure 1 , Table 2 and Table S2 , and results for safety outcomes are shown in Figure 2 , Table 3 and Table S3 . Networks of comparisons are shown in Figure S2 . Figure 1 and Figure 1 and Table S2 ).
Data on body weight were available for 14 054 participants.
Compared with placebo, treatment with GLP-1RAs was associated with significant weight loss, the greatest being with liraglutide ( Figure 1 and Table S2 ).
With the exception of lixisenatide, treatment with all GLP-1RAs significantly raised heart rate compared with placebo, ranging from a minimum of 1.07 bpm (95% CI 0.00, 2.15) with twice-daily exenatide to a maximum of 3.28 bpm (95% CI 2.45, 4.11) with liraglutide ( Figure 1 and Table S2 ).
Compared with placebo, dulaglutide and liraglutide lowered triglycerides, while albiglutide, dulaglutide, once-weekly exenatide and liraglutide lowered both total cholesterol and LDL cholesterol ( Figure 1 and Table S2 ). No clinically meaningful changes in HDL cholesterol level were noted.
| Comparison among GLP-1RAs for cardiometabolic outcomes
Compared with twice-daily exenatide, treatment with dulaglutide, liraglutide, once-weekly exenatide and taspoglutide showed greater Table 2 ).
For SBP, among all possible GLP-1RA comparisons, the only difference was between liraglutide and taspoglutide (2.40 mm Hg; 95% agents, no significant differences were noted for heart rate; similarly, no differences were observed when long-acting agents were compared with each other.
Only marginal differences were found for the lipid profile among all GLP-1RAs ( Table 2 ).
The network meta-analytical comparisons between lixisenatide and other GLP-1RAs for SBP, DBP and lipid variables were not possible from available published RCTs. Statistical inconsistencies of the networks were not significant for all cardiometabolic outcomes.
| Comparison vs placebo for safety outcomes
Total hypoglycaemic events were reported in 12 761 people; all GLP1RAs except albiglutide significantly increased the risk of hypoglycaemia compared with placebo from a minimum OR of 1.59 (95% CI 
| Comparison among GLP-1RAs for safety outcomes
Among all GLP-1RAs comparisons, the risk of hypoglycaemia was not significantly different (Table 3) . Statistical inconsistency was found for hypoglycaemia only in the main analysis (P = .044; analysis excluding background sulphonylurea and insulin, P = .118). The risk of diarrhoea was lower with twice-daily exenatide vs liraglutide (OR 0.67) and with lixisenatide vs liraglutide (OR 0.45), dulaglutide (OR 0.42) and albiglutide (OR 0.40); no significant differences were observed within short-acting or within long-acting agents (Table 3 ). The largest differences amongst all comparisons was between albiglutide and lixisenatide (OR 2.50; 95% CI 1.15, 5.26).
| DISCUSSION
The 1.60, 4.36) 2.17 (1.22, 3.85) 3.67 (1.56, 8.62 1.76, 7.96) 3.07 (1.22, 7.69 Previous studies have shown that GLP-1RAs are effective in reducing body weight and blood pressure compared with placebo. [56] [57] Our results are consistent with these observations as they show a reduction in body weight and particularly in SBP when compared with placebo; however, we did not find clinically meaningful differences across all GLP-1RAs for these two outcomes. Regarding lipid profiles, differences between each GLP-1RA vs placebo and across all GLP-1RAs were clinically marginal.
Notably, the available data showed that twice-daily and onceweekly exenatide, liraglutide and dulaglutide significantly raised heart rate vs placebo, from a minimum of 1.1 bpm for twice-daily exenatide to a maximum of 3.3 bpm for liraglutide. The highest difference was found between liraglutide and lixisenatide (3.5 bpm), although no differences were noted within short-acting agents or within long-acting agents.
Compared with placebo, taspoglutide was associated with the highest (4 times) and lixisenatide with the lowest (1.6 times) risk of hypoglycaemia; however, no differences were noted among all GLP1RAs when compared against each other.
Treatment-associated gastrointestinal symptoms are wellrecognized adverse effects of GLP-1RAs and have been shown to be higher when compared with placebo or with other common glucoselowering therapies. 58 While the present results confirmed an increased risk of gastrointestinal side effects compared with placebo, we also noted important differences among GLP-1RAs for nausea, vomiting and diarrhoea. Albiglutide had the lowest risk of nausea (5 times lower than taspoglutide) and diarrhoea (2.5 times lower than lixisenatide) and once-weekly exenatide of vomiting (5 times lower than taspoglutide).
Overall, the present findings showed that treatments with the long-acting GLP-1RAs dulaglutide, liraglutide and once-weekly exenatide resulted in greater glycaemic efficacy, but not clinically meaningful differences in blood pressure, body weight, lipid profile or risk of hypoglycaemia when compared with short-acting agents. Across these 3 long-acting agents, however, once-weekly exenatide had the lowest risk of nausea and vomiting.
To the best of our knowledge, this is the first attempt to systematically compare all available GLP-1RAs, combining several clinically meaningful efficacy and safety outcomes simultaneously and comprehensively. We pooled data from published RCTs with a mixedtreatment comparison meta-analytical approach, aiming to fulfil the gap in providing decision-makers with evidence to choose the appropriate agents considering the specific advantages and disadvantages of each agent. We therefore collated data for multiple outcomes relevant to clinical practice (ie, HbA1c, FPG, body weight, blood pressure, lipid profile, hypoglycaemia and common gastrointestinal side effects).
We should also acknowledge, however, some shortcomings of the present study. First, it should be noted that postprandial glucose, along with FPG, contributes to overall glycaemic control. 59 Although several studies suggest short-acting GLP-1RAs, lixisenatide and In conclusion, although there were no differences when shortacting agents were compared with each other and when long-acting agents were compared with each other, available data indicate that dulaglutide, liraglutide and once-weekly exenatide are superior to twice-daily exenatide and lixisenatide at lowering HbA1c and FPG levels. There were no differences in hypoglycaemia between these 3 agents, whilst once-weekly exenatide had the lowest risk of nausea and vomiting. The choice of these agents should be tailored, taking into account their differences in safety and efficacy along with patient's targets and needs.
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